PegBio Plans Auditor Switch to Cut Costs; Redirects RMB95.50 Million of IPO Funds Toward PB-119 Commercial Roll-Out

Bulletin Express11-11

PegBio Co., Ltd. (PegBio) has called an extraordinary general meeting (EGM) on 26 November 2026 to seek shareholder approval for three key resolutions: replacing its external auditor, appointing a new auditor, and revising the allocation of unutilised proceeds from its May 2025 Hong Kong IPO.

Auditor Transition • Proposed removal of KPMG: PegBio’s Audit Committee and Board recommend terminating KPMG’s mandate for the FY2026 audit after failing to agree on a RMB3.00 million fee. KPMG confirmed no other disagreements with the Company. • Proposed appointment of Rongcheng (Hong Kong) CPA Limited (RCHK): RCHK’s audit fee is quoted at RMB1.30 million—about 56.7 % lower than KPMG’s offer. The Audit Committee cited RCHK’s AFRC registration, Hong Kong listed-company experience, and a 3,560-hour audit plan as evidence of competence. • Audit timetable: Planning begins December 2026, fieldwork runs through February 2027, and final results are targeted for release by end-March 2027.

Reallocation of IPO Proceeds PegBio raised net proceeds of HK$231.80 million (RMB212.60 million) in its 2025 Global Offering. As at 31 August 2026, RMB163.70 million remains unspent. The Board proposes shifting RMB95.50 million—originally earmarked for four PB-119 clinical R&D projects—into commercialisation and post-marketing studies for PB-119. Key adjustments:

1. Cancelled/Deferred Projects (funds fully reallocated) • Cardiovascular outcomes study: ‑RMB15.30 million • Combination with SGLT-2 inhibitor study: ‑RMB11.90 million • Combination with basal insulin study: ‑RMB11.90 million • PB-119-2 weight-loss development: ‑RMB56.40 million

2. Expanded Budget • Commercialisation & post-marketing studies of PB-119: +RMB95.50 million, raising the remaining allocation to RMB103.70 million, to be fully utilised by end-2027.

Other planned uses—RMB51.90 million for PB-718 development (end-2027), RMB6.10 million for other pipeline R&D (end-2026), and RMB2.00 million for business development (end-2026)—are unchanged. Working-capital funds of RMB19.20 million have already been deployed.

EGM Logistics • Date/Time: 26 November 2026, 10:00 a.m. (HKT) • Venue: 6/F, Block A, No. 520 Shaoxing Road, Gongshu District, Hangzhou, Zhejiang Province, PRC • Record date: 20 November 2026; proxy forms due by 10:00 a.m., 25 November 2026.

Shareholders will vote on: 1. Removal of KPMG as auditor. 2. Appointment of RCHK as auditor and authorisation of its remuneration. 3. Change in use of Global Offering proceeds as outlined above.

The Board asserts that the proposed auditor switch will enhance cost efficiency without compromising audit quality and that the proceeds reallocation aligns with PB-119’s transition from R&D to commercial phase, supporting market access and lifecycle management initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment